Barinthus Bio Cuts Down Workforce by 25%

Taking a new path for pipeline reorganisation and prioritising results in Barinthus Bio axing its prostate cancer candidate and significantly reducing staff.

The UK T cell expert declared that it will concentrate its development efforts on two immunotherapy applicants, VTP-300 and VTP-1000, for targets related to coeliac disease and chronic hepatitis B.

Barinthus’ CEO Bill Enright explained: “We believe that VTP-300 has great potential to do so as part of a functional cure regimen for Hepatitis B. With this pipeline prioritisation, we put the company in a strong position to maximise the probability of success.”

The biopharma added that it anticipates going through a restructure during the course of the pipeline shuffle, which will involve cutting its workforce by about a quarter.